MARKET

EVFM

EVFM

Evofem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
-0.060
-5.17%
After Hours: 1.120 +0.02 +1.82% 19:58 06/18 EDT
OPEN
1.170
PREV CLOSE
1.160
HIGH
1.230
LOW
1.100
VOLUME
15.70M
TURNOVER
--
52 WEEK HIGH
5.53
52 WEEK LOW
0.7510
MARKET CAP
113.12M
P/E (TTM)
-0.4693
1D
5D
1M
3M
1Y
5Y
Bionano Genomics to join Russel 3000 Index, while AcelRx Pharmaceuticals to see deletion among healthcare stocks
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen
Seekingalpha · 5d ago
Thinking about buying stock in Evofem Biosciences, Clean Energy Fuels, Luokung Technology, Mediaco Holding, or FuelCell Energy?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, CLNE, LKCO, MDIA, and FCEL.
PR Newswire - PRF · 6d ago
22 Stocks Moving in Monday's Pre-Market Session
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) rose 73.4% to $6.66 in pre-market trading. MediaCo, last week, named Rahsan-Rahsan Lindsay as Chief Executive Officer, effective July 1, 2021.
Benzinga · 6d ago
Evofem Biosciences Inc (EVFM) CEO Saundra L Pelletier Bought $51,500 of Shares
GuruFocus News · 06/11 22:15
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 06/11 16:48
Thinking about buying stock in Amesite, ContextLogic, Sundial Growers, Evofem Biosciences, or Curis?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMST, WISH, SNDL, EVFM, and CRIS.
PR Newswire - PRF · 06/11 15:00
Healthcare names dominate premarket gainers
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor
Seekingalpha · 06/11 12:28
Thinking about buying stock in Naked Brand, Palantir Technologies, Nokia, Evofem Biosciences, or Micron?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, PLTR, NOK, EVFM, and MU.
PR Newswire - PRF · 06/08 15:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVFM. Analyze the recent business situations of Evofem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVFM stock price target is 6.40 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 190
Institutional Holdings: 64.43M
% Owned: 62.65%
Shares Outstanding: 102.84M
TypeInstitutionsShares
Increased
31
5.27M
New
31
8.55M
Decreased
21
3.74M
Sold Out
18
701.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.19%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Non-Executive Chairman/Independent Director
William Hall
President/Chief Executive Officer/Director
Saundra Pelletier
Chief Financial Officer
Justin File
Executive Vice President/General Counsel/Secretary
Alexander Fitzpatrick
Other
Russell Barrans
Other
Russ Barrans
Other
Kelly Culwell
Independent Director
Gillian Greer
Independent Director
Kim Kamdar
Independent Director
Tony O'Brien
Independent Director
Lisa Rarick
Independent Director
Colin Rutherford
No Data
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs). The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd.

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.